Literature DB >> 20571983

Metachromatic leukodystrophy--an update.

V Gieselmann1, I Krägeloh-Mann.   

Abstract

Metachromatic leukodystrophy (MLD) is a rare lysosomal sphingolipid storage disorder, caused by a deficiency of arylsulfatase A (ASA). It is inherited in an autosomal recessive way, among Caucasians three causing alleles are frequent. Demyelination is the hallmark of MLD. Interest in the disease has increased as therapeutic options such as stem cell transplantation, enzyme replacement and gene therapy are topics of current research. A late-infantile (onset before 3 years of age), a juvenile form (onset before 16 years) and an adult form are usually distinguished. Rapid motor decline is typical for the first and also the second forms, the second may be preceded by cognitive and behavioural problems, which mainly characterize the adult form. There is evidence for a genotype-phenotype correlation: patients homozygous for alleles which do not allow the expression of any enzyme activity (null-allele) suffer from the late infantile form; heterozygosity for a null allele and a non-null allele are more associated with the juvenile form and homozygosity for non-null alleles is more frequent in the most attenuated adult onset form.

Entities:  

Mesh:

Year:  2010        PMID: 20571983     DOI: 10.1055/s-0030-1253412

Source DB:  PubMed          Journal:  Neuropediatrics        ISSN: 0174-304X            Impact factor:   1.947


  48 in total

Review 1.  Mesenchymal stem cells as cellular vectors for pediatric neurological disorders.

Authors:  Donald G Phinney; Iryna A Isakova
Journal:  Brain Res       Date:  2014-05-22       Impact factor: 3.252

Review 2.  Gene therapy for metachromatic leukodystrophy.

Authors:  Jonathan B Rosenberg; Stephen M Kaminsky; Patrick Aubourg; Ronald G Crystal; Dolan Sondhi
Journal:  J Neurosci Res       Date:  2016-11       Impact factor: 4.164

3.  Arylsulfatase A Overexpressing Human iPSC-derived Neural Cells Reduce CNS Sulfatide Storage in a Mouse Model of Metachromatic Leukodystrophy.

Authors:  Jonas Doerr; Annika Böckenhoff; Benjamin Ewald; Julia Ladewig; Matthias Eckhardt; Volkmar Gieselmann; Ulrich Matzner; Oliver Brüstle; Philipp Koch
Journal:  Mol Ther       Date:  2015-06-10       Impact factor: 11.454

4.  Comparative efficacy and safety of multiple routes of direct CNS administration of adeno-associated virus gene transfer vector serotype rh.10 expressing the human arylsulfatase A cDNA to nonhuman primates.

Authors:  Jonathan B Rosenberg; Dolan Sondhi; David G Rubin; Sébastien Monette; Alvin Chen; Sara Cram; Bishnu P De; Stephen M Kaminsky; Caroline Sevin; Patrick Aubourg; Ronald G Crystal
Journal:  Hum Gene Ther Clin Dev       Date:  2014-08-21       Impact factor: 5.032

5.  Hereditary diffuse leukoencephalopathy with axonal spheroids (HDLS): a misdiagnosed disease entity.

Authors:  Christina Sundal; Jennifer Lash; Jan Aasly; Sarka Øygarden; Sigrun Roeber; Hans Kretzschman; James Y Garbern; Alex Tselis; Rosa Rademakers; Dennis W Dickson; Daniel Broderick; Zbigniew K Wszolek
Journal:  J Neurol Sci       Date:  2011-11-01       Impact factor: 3.181

6.  Myelin phagocytosis by astrocytes after myelin damage promotes lesion pathology.

Authors:  Gerald Ponath; Sriram Ramanan; Mayyan Mubarak; William Housley; Seunghoon Lee; F Rezan Sahinkaya; Alexander Vortmeyer; Cedric S Raine; David Pitt
Journal:  Brain       Date:  2016-12-21       Impact factor: 13.501

7.  Cerebral gray and white matter changes and clinical course in metachromatic leukodystrophy.

Authors:  Samuel Groeschel; Christine í Dali; Philipp Clas; Judith Böhringer; Morten Duno; Christian Krarup; Christiane Kehrer; Marko Wilke; Ingeborg Krägeloh-Mann
Journal:  Neurology       Date:  2012-09-19       Impact factor: 9.910

8.  Metachromatic leukodystrophy: natural course of cerebral MRI changes in relation to clinical course.

Authors:  Samuel Groeschel; Christiane Kehrer; Corinna Engel; Christine I Dali; Annette Bley; Robert Steinfeld; Wolfgang Grodd; Ingeborg Krägeloh-Mann
Journal:  J Inherit Metab Dis       Date:  2011-06-23       Impact factor: 4.982

Review 9.  Gene therapy returns to centre stage.

Authors:  Luigi Naldini
Journal:  Nature       Date:  2015-10-15       Impact factor: 49.962

Review 10.  Neurometabolic disorders: Five new things.

Authors:  Michèl A Willemsen; Inga Harting; Ron A Wevers
Journal:  Neurol Clin Pract       Date:  2016-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.